A critical clinical distinction has emerged from regulatory guidance: antihistamines and corticosteroids are completely ineffective against bradykinin-mediated angioedema, yet remain the default treatment approach in many clinical settings. According to MHRA data, while these medications successfully resolve histamine-mediated angioedema, they provide no therapeutic benefit—and potentially delay appropriate specialist care—when bradykinin accumulation is the underlying mechanism. ACE inhibitors prevent bradykinin breakdown, leading to vascular permeability and inflammation through a distinct biochemical pathway unrelated to histamine release. This means patients receiving antihistamines or corticosteroids for bradykinin-mediated cases experience treatment failure despite appropriate medication dosing. The timing of onset adds complexity: angioedema can develop after months or years of stable ACE inhibitor therapy, catching clinicians off guard and leading to misclassification. Healthcare providers must now recognize that two separate treatment algorithms exist for what appears clinically similar, requiring rapid diagnostic precision to guide management toward bradykinin antagonists when appropriate. Read the full article on GMJ Newsroom.
Was this article helpful?
